vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and OFF THE HOOK YS INC. (OTH). Click either name above to swap in a different company.
OFF THE HOOK YS INC. is the larger business by last-quarter revenue ($24.0M vs $19.1M, roughly 1.3× NewAmsterdam Pharma Co N.V.). OFF THE HOOK YS INC. runs the higher net margin — -0.3% vs -90.7%, a 90.4% gap on every dollar of revenue. OFF THE HOOK YS INC. produced more free cash flow last quarter ($-867.2K vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMS vs OTH — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $24.0M |
| Net Profit | $-17.4M | $-66.7K |
| Gross Margin | — | 12.6% |
| Operating Margin | -186.1% | 1.3% |
| Net Margin | -90.7% | -0.3% |
| Revenue YoY | 740.1% | — |
| Net Profit YoY | 55.5% | — |
| EPS (diluted) | $-0.15 | $-0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $24.0M | ||
| Q2 25 | $19.1M | — | ||
| Q4 24 | $12.8M | — | ||
| Q3 24 | $29.1M | — | ||
| Q2 23 | $8.6M | — |
| Q3 25 | — | $-66.7K | ||
| Q2 25 | $-17.4M | — | ||
| Q4 24 | $-92.2M | — | ||
| Q3 24 | $-16.6M | — | ||
| Q2 23 | $-42.0M | — |
| Q3 25 | — | 12.6% | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | — | 1.3% | ||
| Q2 25 | -186.1% | — | ||
| Q4 24 | -338.5% | — | ||
| Q3 24 | -85.9% | — | ||
| Q2 23 | -461.8% | — |
| Q3 25 | — | -0.3% | ||
| Q2 25 | -90.7% | — | ||
| Q4 24 | -721.7% | — | ||
| Q3 24 | -57.2% | — | ||
| Q2 23 | -486.9% | — |
| Q3 25 | — | $-0.00 | ||
| Q2 25 | $-0.15 | — | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 23 | $-0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $2.3M |
| Total DebtLower is stronger | — | $287.2K |
| Stockholders' EquityBook value | $778.5M | $-610.5K |
| Total Assets | $815.1M | $32.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $2.3M | ||
| Q2 25 | $739.2M | — | ||
| Q4 24 | $834.2M | — | ||
| Q3 24 | $422.7M | — | ||
| Q2 23 | — | — |
| Q3 25 | — | $287.2K | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | — | $-610.5K | ||
| Q2 25 | $778.5M | — | ||
| Q4 24 | $757.5M | — | ||
| Q3 24 | $378.9M | — | ||
| Q2 23 | $398.4M | — |
| Q3 25 | — | $32.6M | ||
| Q2 25 | $815.1M | — | ||
| Q4 24 | $864.6M | — | ||
| Q3 24 | $439.2M | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-664.2K |
| Free Cash FlowOCF − Capex | $-37.8M | $-867.2K |
| FCF MarginFCF / Revenue | -197.2% | -3.6% |
| Capex IntensityCapex / Revenue | 0.5% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-664.2K | ||
| Q2 25 | $-37.7M | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.5M | — | ||
| Q2 23 | $-31.9M | — |
| Q3 25 | — | $-867.2K | ||
| Q2 25 | $-37.8M | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 23 | $-31.9M | — |
| Q3 25 | — | -3.6% | ||
| Q2 25 | -197.2% | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q2 23 | -369.3% | — |
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.5% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 23 | 0.1% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
